VIVS underwent a complete business transformation from a clinical-stage IBD drug developer (Organovo) to a pharmaceutical services company (VivoSim Labs) providing 3D tissue testing, accompanied by a 1-for-12 reverse stock split and dramatic financial improvements.
This represents a fundamental pivot in business strategy from developing proprietary therapeutics to offering contract research services, which typically involves lower risk but also lower potential returns. The company name change, reverse stock split, and complete shift in business description suggest either a strategic repositioning after clinical setbacks or a response to financial distress in the previous drug development model.
The financial transformation is striking, with revenue surging 299% to $4.6M and net losses improving dramatically from -$14.7M to -$2.5M, while stockholders' equity increased an exceptional 2,782% to $10.5M primarily through a major cash infusion that boosted cash equivalents to $11.3M. The improved operating cash flow (-$9.5M vs -$14.7M) and reduced capital expenditures suggest the new services-based model requires less upfront investment than drug development. Overall, the financials indicate a successful capital raise that funded the business transformation and put the company on much stronger financial footing, though investors should monitor whether the new revenue model can sustain profitability.
Equity base grew 2782.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Strong top-line growth of 299.2% — accelerating demand or successful expansion into new markets.
Cash position surged 289.9% — strong cash generation or capital raise providing significant financial cushion.
Current assets grew 208.2% — improving short-term liquidity or inventory/receivables build.
Asset base grew 130.7% — expansion through organic growth, acquisitions, or capital deployment.
Current liabilities surged 100.9% — significant near-term obligations; verify ability to meet short-term debt.
Net income grew 83% — bottom-line growth signals improving overall business health.
Capex reduced 69% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Liabilities grew 51.3% — significant increase in debt or obligations, assess impact on financial flexibility.
Operating cash flow surged 35.4% — exceptional cash generation, highest quality earnings signal.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →